BLAINJECTIONINJECTABLE
Approved
Sep 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HUMEGON is a menotropin injection containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH), approved in 1994 for fertility treatment. It stimulates ovarian follicle development and hormone production in assisted reproductive therapy. The product is indicated for patients requiring gonadotropin therapy in fertility protocols.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); small linked job footprint suggests minimal brand team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Merck & Co. is hiring 1 role related to this product
Worked on HUMEGON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.